By: DengYue International Business DivisionTen years ago, China was known primarily as a supplier of APIs and low-cost generic medicines to the world. Today, if someone tells you that China is developing, manufacturing, and exporting world-class oncology drugs, biologics, ...Learn More

As November 2025 arrives, the global pharmaceutical industry stands at a pivotal moment.In October alone, China saw six innovative drugs approved for market launch, including the world’s first EGFR-targeting Antibody–Drug Conjugate (ADC), Becotatugvedotin for Injection.This ...Learn More

Antibody–Drug Conjugates (ADCs): Leading the Global Oncology RevolutionAs cancer treatment enters the era of precision and personalization, Antibody–Drug Conjugates (ADCs)—often referred to as “biological missiles”—represent one of the highest frontiers of ...Learn More

BOC Sciences is teaming up with innovators at the PODD Conference 2025 to fast-track the next generation of drug delivery. The future of medicine rests, in large part, on effective delivery systems. With the industry rushing to harness the potential of advanced therapeutics — ...Learn More

Creative Biolabs reveals the development methodologies for bispecifics for specific targeting purposes.The global biopharmaceutical industry is buzzing over the next wave of immunotherapy breakthroughs, and bispecific antibodies (bsAbs) are among them to have a serious moment in ...Learn More